NCT01396005View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Hepatitis C Virus
Interventions
DRUG

boceprevir

boceprevir 800 mg (4 x 200 mg capsules), orally, every 8 hours, Day 2 through Day 7

DRUG

methadone

methadone, 20-150 mg tablets, liquid, or disket, orally, once per day, Day 1 through Day 8

DRUG

buprenorphine/naloxone

buprenorphine/naloxone 8/2-24/6 mg, tablets, sublingual, once per day, Day 1 through Day 8

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01396005 - A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123) | Biotech Hunter | Biotech Hunter